(Q37815623)

23 August 2017

1 reference

title

Treatment of triple negative breast cancer (TNBC): current options and future perspectives (English)

1 reference

23 August 2017

1 reference

0 references

Michelino De Laurentiis

1 reference

ORCID Public Data File 2021

author name string

M De Laurentiis

1

1 reference

23 August 2017

D Cianniello

2

1 reference

23 August 2017

R Caputo

3

1 reference

23 August 2017

B Stanzione

4

1 reference

23 August 2017

G Arpino

5

1 reference

23 August 2017

S Cinieri

6

1 reference

23 August 2017

V Lorusso

7

1 reference

23 August 2017

S De Placido

8

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

Cancer Treatment Reviews

1 reference

23 August 2017

36 Suppl 3

1 reference

23 August 2017

S80-6

1 reference

Triple-negative breast cancer--current status and future directions

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Pharmacotherapy of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Triple-negative breast cancer: novel therapies and new directions.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Adjuvant therapy of triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Genome maintenance mechanisms for preventing cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

BRCA2 is required for homology-directed repair of chromosomal breaks

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Brca1 controls homology-directed DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Poly(ADP-ribose): novel functions for an old molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

PARP inhibitors for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

The potential role and application of PARP inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Erlotinib-induced breast cancer regression

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970025-6

7 January 2021

10.1016/S0305-7372(10)70025-6

Identifiers

DOI

1 reference

release_aezjg4bsmncpxf4xvqlzda3kda

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aezjg4bsmncpxf4xvqlzda3kda

24 November 2022

mapped directly with Wikidata item

1 reference